CSPC Baike (Shandong) Biopharmaceutical
Clinical trials sponsored by CSPC Baike (Shandong) Biopharmaceutical, explained in plain language.
Pharmaceutical subsidiary of CSPC Group, developing biologics.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Healthy volunteers needed to test new injection method for experimental drug Results expected Oct 2026 (estimated)
-
New Weight-Loss shot shows promise in major trial
Disease control CompletedThis study tested a new weekly injection (HD1916) similar to semaglutide for weight loss in 462 obese adults without diabetes. Participants received the drug for 44 weeks, and researchers measured how much weight they lost and any side effects. The goal was to see if this treatme…
Phase 3 • Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New weekly diabetes shot shows promise in large trial
Disease control CompletedThis Phase 3 trial tested a new weekly injection called TG103, combined with the common diabetes pill metformin, in 632 adults with type 2 diabetes. The goal was to see if TG103 could lower blood sugar better than an existing weekly shot (dulaglutide) over 28 weeks. Participants …
Phase 3 • Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Weekly shot shows promise for diabetes control in major trial
Disease control CompletedThis study tested a new weekly injection called TG103 in 465 adults with type 2 diabetes whose blood sugar was not well controlled by diet and exercise alone. Participants received either a low dose, a higher dose, or a placebo for several weeks. The main goal was to see if TG103…
Phase 3 • Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC